Ardsley Advisory Partners cut its position in Abeona Therapeutics Inc (NASDAQ:ABEO) by 20.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 40,000 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the quarter. Ardsley Advisory Partners’ holdings in Abeona Therapeutics were worth $634,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ABEO. Viking Global Investors LP raised its holdings in Abeona Therapeutics by 80.5% in the fourth quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock worth $64,046,000 after purchasing an additional 1,802,007 shares during the period. State Street Corp acquired a new stake in Abeona Therapeutics in the second quarter worth $1,900,000. BlackRock Inc. raised its holdings in Abeona Therapeutics by 15.1% in the fourth quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after purchasing an additional 245,217 shares during the period. Sphera Funds Management LTD. acquired a new stake in Abeona Therapeutics in the fourth quarter worth $3,329,000. Finally, Point72 Asset Management L.P. acquired a new stake in Abeona Therapeutics in the third quarter worth $3,527,000. Institutional investors own 62.64% of the company’s stock.
Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) opened at $15.80 on Tuesday. Abeona Therapeutics Inc has a twelve month low of $4.55 and a twelve month high of $22.75. The company has a market cap of $739.05, a price-to-earnings ratio of -24.31 and a beta of 1.42.
WARNING: “Ardsley Advisory Partners Has $634,000 Holdings in Abeona Therapeutics Inc (ABEO)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3258716/ardsley-advisory-partners-has-634000-holdings-in-abeona-therapeutics-inc-abeo.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc (NASDAQ:ABEO).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.